IT1298487B1 - Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, - Google Patents

Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

Info

Publication number
IT1298487B1
IT1298487B1 IT97RM000796A ITRM970796A IT1298487B1 IT 1298487 B1 IT1298487 B1 IT 1298487B1 IT 97RM000796 A IT97RM000796 A IT 97RM000796A IT RM970796 A ITRM970796 A IT RM970796A IT 1298487 B1 IT1298487 B1 IT 1298487B1
Authority
IT
Italy
Prior art keywords
ptx3
therapy
infectious
inflammatory
pharmaceutical compositions
Prior art date
Application number
IT97RM000796A
Other languages
English (en)
Inventor
Barbara Bottazzi
Martino Introna
Alberto Mantovani
Annunciata Vecchi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IT97RM000796A priority Critical patent/IT1298487B1/it
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to PCT/IT1998/000364 priority patent/WO1999032516A2/en
Priority to EP98962665A priority patent/EP1034185B1/en
Priority to ES98962665T priority patent/ES2242309T3/es
Priority to NZ505063A priority patent/NZ505063A/xx
Priority to DE69830251T priority patent/DE69830251T2/de
Priority to JP2000525453A priority patent/JP4173633B2/ja
Priority to AU17829/99A priority patent/AU756974B2/en
Priority to DK98962665T priority patent/DK1034185T3/da
Priority to SI9830763T priority patent/SI1034185T1/xx
Priority to KR1020007006739A priority patent/KR100560085B1/ko
Priority to PT98962665T priority patent/PT1034185E/pt
Priority to CA2315277A priority patent/CA2315277C/en
Priority to AT98962665T priority patent/ATE295853T1/de
Publication of ITRM970796A1 publication Critical patent/ITRM970796A1/it
Application granted granted Critical
Publication of IT1298487B1 publication Critical patent/IT1298487B1/it
Priority to US11/882,180 priority patent/US8003109B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT97RM000796A 1997-12-19 1997-12-19 Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, IT1298487B1 (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IT97RM000796A IT1298487B1 (it) 1997-12-19 1997-12-19 Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
KR1020007006739A KR100560085B1 (ko) 1997-12-19 1998-12-16 긴 펜트락신 ｐｔｘ3를 포함하는 약제학적 조성물
ES98962665T ES2242309T3 (es) 1997-12-19 1998-12-16 Composiciones farmaceuticas que contienen pentraxina larga ptx3.
NZ505063A NZ505063A (en) 1997-12-19 1998-12-16 Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
DE69830251T DE69830251T2 (de) 1997-12-19 1998-12-16 Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
JP2000525453A JP4173633B2 (ja) 1997-12-19 1998-12-16 長いペントラキシンｐｔｘ３を含む医薬組成物
PCT/IT1998/000364 WO1999032516A2 (en) 1997-12-19 1998-12-16 Pharmaceutical compositions containing the long pentraxin ptx3
DK98962665T DK1034185T3 (da) 1997-12-19 1998-12-16 Farmaceutisk sammensætning indeholdende den lange pentraxin PTX3
SI9830763T SI1034185T1 (it) 1997-12-19 1998-12-16
EP98962665A EP1034185B1 (en) 1997-12-19 1998-12-16 Pharmaceutical compositions containing the long pentraxin ptx3
PT98962665T PT1034185E (pt) 1997-12-19 1998-12-16 Composicoes farmaceuticas que contem a pentraxina longa ptx3
CA2315277A CA2315277C (en) 1997-12-19 1998-12-16 Pharmaceutical compositions containing the long pentraxin ptx3
AT98962665T ATE295853T1 (de) 1997-12-19 1998-12-16 Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
AU17829/99A AU756974B2 (en) 1997-12-19 1998-12-16 Pharmaceutical compositions containing the long pentraxin PTX3
US11/882,180 US8003109B2 (en) 1997-12-19 2007-07-31 Pharmaceutical compositions containing the long pentraxin PTX3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97RM000796A IT1298487B1 (it) 1997-12-19 1997-12-19 Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

Publications (2)

Publication Number Publication Date
ITRM970796A1 ITRM970796A1 (it) 1999-06-19
IT1298487B1 true IT1298487B1 (it) 2000-01-10

Family

ID=11405409

Family Applications (1)

Application Number Title Priority Date Filing Date
IT97RM000796A IT1298487B1 (it) 1997-12-19 1997-12-19 Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

Country Status (13)

Country Link
US (1) US8003109B2 (it)
EP (1) EP1034185B1 (it)
JP (1) JP4173633B2 (it)
KR (1) KR100560085B1 (it)
AT (1) ATE295853T1 (it)
AU (1) AU756974B2 (it)
CA (1) CA2315277C (it)
DE (1) DE69830251T2 (it)
ES (1) ES2242309T3 (it)
IT (1) IT1298487B1 (it)
NZ (1) NZ505063A (it)
PT (1) PT1034185E (it)
WO (1) WO1999032516A2 (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US7041648B2 (en) 2001-08-03 2006-05-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions and methods for treating female fertility
DK1411971T3 (da) * 2001-08-03 2006-08-07 Sigma Tau Ind Farmaceuti Anvendelse af lang gentraxin PTX3 til behandling af kvindelig sterilitet
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ITRM20040223A1 (it) 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1973944B1 (en) * 2006-01-24 2016-05-11 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Fgf2-binding peptides and uses thereof
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
RS52377B (en) * 2006-05-02 2012-12-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Administration of thymosin 1, alone or in combination with PTX3 or ganciclovir, for the treatment of CITOMEGALOVIRUS INFECTION
WO2009095403A1 (en) * 2008-01-29 2009-08-06 Tecnogen S.P.A. Expression system and uses thereof for the production of human long pentraxin 3
US8883446B2 (en) 2009-07-29 2014-11-11 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Human long pentraxin 3 expression system and uses thereof
KR101305515B1 (ko) 2011-06-10 2013-09-06 경북대학교 산학협력단 펜트락신 3 단백질의 파킨슨 질환 진단 용도
EP2865384B1 (en) * 2012-06-22 2018-08-15 The University of Tokyo Agent for treating or preventing systemic inflammatory response syndrome
TWI528969B (zh) 2013-06-07 2016-04-11 國立成功大學 胺基酸序列用於製備抑制ｐｔｘ３治療鼻咽癌之醫藥組合物之用途
TWI531375B (zh) 2015-05-29 2016-05-01 國立成功大學 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物
CN105132459B (zh) * 2015-09-14 2019-01-29 武汉市星熠艾克生物医药有限责任公司 人类ptx3重组蛋白的制备方法及应用
WO2021230233A1 (ja) * 2020-05-14 2021-11-18 学校法人日本医科大学 感染症の治療又は予防剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
JPH06506195A (ja) * 1991-01-14 1994-07-14 ニューヨーク　ユニバシテイ サイトカイン誘導タンパク質、ｔｓｇ−１４、そのためのｄｎａコード化およびその使用
IT1254687B (it) * 1992-04-14 1995-09-28 Italfarmaco Spa Gene inducibile da citochine
US6210941B1 (en) 1997-06-27 2001-04-03 The Trustees Of Boston University Methods for the detection and isolation of proteins
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US6872541B2 (en) 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US7041648B2 (en) 2001-08-03 2006-05-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions and methods for treating female fertility
DK1411971T3 (da) 2001-08-03 2006-08-07 Sigma Tau Ind Farmaceuti Anvendelse af lang gentraxin PTX3 til behandling af kvindelig sterilitet
US20040137544A1 (en) 2002-10-31 2004-07-15 Roberto Latini PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
US20070036744A1 (en) 2003-04-23 2007-02-15 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1832295A1 (en) 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
RS52377B (en) 2006-05-02 2012-12-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Administration of thymosin 1, alone or in combination with PTX3 or ganciclovir, for the treatment of CITOMEGALOVIRUS INFECTION

Also Published As

Publication number Publication date
JP2002503642A (ja) 2002-02-05
US8003109B2 (en) 2011-08-23
NZ505063A (en) 2002-12-20
WO1999032516A3 (en) 1999-10-28
PT1034185E (pt) 2005-07-29
AU1782999A (en) 1999-07-12
WO1999032516A2 (en) 1999-07-01
CA2315277C (en) 2010-02-23
DE69830251D1 (de) 2005-06-23
CA2315277A1 (en) 1999-07-01
KR100560085B1 (ko) 2006-03-13
EP1034185B1 (en) 2005-05-18
ATE295853T1 (de) 2005-06-15
KR20010033297A (ko) 2001-04-25
US20080015153A1 (en) 2008-01-17
EP1034185A2 (en) 2000-09-13
DE69830251T2 (de) 2005-10-27
ES2242309T3 (es) 2005-11-01
JP4173633B2 (ja) 2008-10-29
ITRM970796A1 (it) 1999-06-19
AU756974B2 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ATE396266T1 (de) Trp8 krebsmarker
BR9407956A (pt) Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
NL990033I1 (nl) Tumornecrosefactor, werkwijzen om het te bereiden,samenstellingen die het bevatten, DNA dat ervoor codeert en proefmethoden met dergelijk DNA.
TW428026B (en) Bifunctional protein, preparation and use
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
HUP9903921A2 (hu) Tumor nekrózis faktorral rokon ligandum
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
ATE293700T1 (de) Adenovirus mit glutathion peroxydate gene
DK2182064T3 (da) Gen udtrykt i prostatakræft
IL126152A0 (en) Recombinant adenoviral vectors for human tumor gene therapy
PT1144600E (pt) Ácidos nucleicos akt-3, polipeptídeos e as suas utilizações
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
NO932101L (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
BRPI0415296A (pt) cdna modificado para os nìveis de expressão elevados do fator viii e seus derivados
RU95101019A (ru) Способ получения фактора некроза опухоли, фактор некроза опухоли, днк, клетка, композиция

Legal Events

Date Code Title Description
0001 Granted